Disc Medicine resumed with a Buy at Stifel

Stifel analyst Stephen Willey resumed coverage of Disc Medicine (IRON) with a Buy rating and $125 price target The firm believes the company’s clinical-stage portfolio of assets targeting heme biosynthesis and iron bioavailability will prove clinically and commercially relevant across a broad spectrum of hematological disorders, the analyst tells investors. The firm believes the CNPV-accelerated commercialization of bitopertin in erythropoietic and X-linked protoporphyria and favorable confirmatory Phase 3 APOLLO trial prospects “create a clear path to longer-term profitability,” the analyst added.